Switch theme
Sign up to access all valuation multiples
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
2013
65
Last FY Revenue n/a
LTM EBITDA -$213M
$768M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Spyre Therapeutics has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$213M.
In the most recent fiscal year, Spyre Therapeutics achieved revenue of n/a and an EBITDA of -$209M.
Spyre Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Spyre Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$213M | XXX | -$209M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$217M | XXX | -$209M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$206M | XXX | -$208M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Spyre Therapeutics's stock price is $15.
Spyre Therapeutics has current market cap of $922M, and EV of $768M.
See Spyre Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $768M | $922M | XXX | XXX | XXX | XXX | $-3.14 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Spyre Therapeutics has market cap of $922M and EV of $768M.
Spyre Therapeutics's trades at 866.7x EV/Revenue multiple, and -3.7x EV/EBITDA.
Equity research analysts estimate Spyre Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Spyre Therapeutics has a P/E ratio of -4.5x.
See valuation multiples for Spyre Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $922M | XXX | $922M | XXX | XXX | XXX |
| EV (current) | $768M | XXX | $768M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 866.7x | XXX | XXX | XXX |
| EV/EBITDA | -3.6x | XXX | -3.7x | XXX | XXX | XXX |
| EV/EBIT | -3.5x | XXX | -3.7x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -4.5x | XXX | -4.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -4.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSpyre Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $3.2M for the same period.
Spyre Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Spyre Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Spyre Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 3% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $3.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Spyre Therapeutics acquired XXX companies to date.
Last acquisition by Spyre Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Spyre Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Spyre Therapeutics founded? | Spyre Therapeutics was founded in 2013. |
| Where is Spyre Therapeutics headquartered? | Spyre Therapeutics is headquartered in United States of America. |
| How many employees does Spyre Therapeutics have? | As of today, Spyre Therapeutics has 65 employees. |
| Who is the CEO of Spyre Therapeutics? | Spyre Therapeutics's CEO is Dr. Cameron Turtle, D.Phil.. |
| Is Spyre Therapeutics publicy listed? | Yes, Spyre Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Spyre Therapeutics? | Spyre Therapeutics trades under SYRE ticker. |
| When did Spyre Therapeutics go public? | Spyre Therapeutics went public in 2016. |
| Who are competitors of Spyre Therapeutics? | Similar companies to Spyre Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Spyre Therapeutics? | Spyre Therapeutics's current market cap is $922M |
| Is Spyre Therapeutics profitable? | Yes, Spyre Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Spyre Therapeutics? | Spyre Therapeutics's last 12 months EBITDA is -$213M. |
| What is the current EV/EBITDA multiple of Spyre Therapeutics? | Current EBITDA multiple of Spyre Therapeutics is -3.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
